B2M

Across TCGA pan-cancer cohorts, B2M Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated B2M data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher B2M Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated B2M expression acts as an unfavorable survival marker.

LUSC, SCLC, and SKCM are the cancer types where B2M Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.138	0.818	.003	12	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
SKCM	OS	Median	All	0.352	0.788	.005	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

B2M–LUSC (OS)

Open the LUSC breakdown →